BBVA USA’s Amedisys AMED Stock Holding History

BBVA USA’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Hold	8	–	–	﹤0.01%	940
2021 Q2	$2K	Buy	+8	New	+$2.1K	﹤0.01%	961

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BBVA USA's AMED Position: Q3 2021 in Review

BBVA USA held its Amedisys (AMED) position steady in Q3 2021 at 8 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

BBVA USA first reported a position in AMED in Q2 2021 and has held it in 2 quarters since. The position peaked at $2K in Q2 2021. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

BBVA USA held 8 shares of Amedisys worth $1K as of Q3 2021.
BBVA USA left its Amedisys share count unchanged in Q3 2021.
Amedisys made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #940 holding.
BBVA USA first reported a position in Amedisys in Q2 2021 and has held it in 2 quarters since.
BBVA USA's Amedisys position peaked at $2K in Q2 2021.
351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.